Nektar Therapeutics
NASDAQ:NKTRBiotechnology
-$1.24 today
- Market cap
- $987.44M
- Beta
- 1.15
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$6.39
Volume 0.71M
Average 1.00M
NKTR Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Nektar TherapeuticsNASDAQ: NKTR
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin declines year over year
Q2 FY2026 selling, general & admin of $12.77M fell 25.2% year over year, ahead of the -31.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 3.9% from the prior quarter. Over 3 fiscal years it compounded at -9.4% a year.
Context
- Selling, general & admin amounted to 124.3% of revenue in FY2025, up 46.4 pp from a year earlier.
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 13 analysts of $41.26M (-39.9%) for the fiscal year ending Dec 2026, a slowdown from the -10.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $12.77M-3.9% QoQ
- Last fiscal yearDec 2025
- $68.67M-10.5% YoY
- LTMJun 2026
- $53.31M-31.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 68.67M USD
- Year-over-year change
- -10.5%
- 4-year CAGR
- -13.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 68.67M | -10.5% |
| FY2024 | 2024-12-31 | 76.75M | -0.9% |
| FY2023 | 2023-12-31 | 77.42M | -16.2% |
| FY2022 | 2022-12-31 | 92.33M | -24.8% |
| FY2021 | 2021-12-31 | 122.84M | — |
Selling, General & Admin vs competitors
How NKTR compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -31.2% is the lowest of 10, against a peer median of -6.3%.
- Selling, general & admin amounts to 97.7% of revenue for NKTR, versus a peer median of 90.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.41M USD | -3.4% | — | 39.2% | |
| LTM Jun 2026 | $106M USD | -7.8% | +1.9% | 90.6% | |
| LTM Mar 2026 | $95.58M USD | -30.3% | -20.7% | 203.9% | |
| LTM Jun 2026 | $65.29M USD | +5.1% | +10.3% | 62.2% | |
| LTM Mar 2026 | €53.63M EUR | +14.4% | +12.3% | 143.8% | |
| LTM Jun 2026 | $53.31M USD | -31.2% | -9.4% | 97.7% | |
| LTM Mar 2026 | $38.15M USD | -27.9% | -12.7% | 24.3% | |
| LTM Jun 2024 | $14.78M USD | — | -14.4% | 227.7% | |
| FY2025 | €11M EUR | -7.8% | -8.7% | 394.7% | |
| LTM Mar 2026 | $10.49M USD | +24.0% | +4.5% | — | |
| LTM Mar 2026 | $9.36M USD | -6.3% | -5.7% | 12.9% | |
| Peer median (excluding NKTR) | — | -6.3% | -5.7% | 90.6% | |
Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 101.91M | 92.06M | 90.12M | 98.43M | 55.23M |
| Cost of Revenue | 24.9M | 21.64M | 36.64M | 30.69M | 0 |
| Gross Profit | 77.01M | 70.42M | 53.48M | 67.74M | 55.23M |
| Gross Margin | 75.6% | 76.5% | 59.3% | 68.8% | 100.0% |
| Research & Development | 400.27M | 218.32M | 114.16M | 120.91M | 117.33M |
| Selling, General & Admin | 122.84M | 92.33M | 77.42M | 76.75M | 68.67M |
| Operating Expenses | 523.11M | 310.66M | 190.9M | 172.94M | 186M |
| Depreciation & Amortization | 14.15M | 12.2M | 7.82M | 4.39M | 1.03M |
| EBITDA | (461.82M) | (323.87M) | (243.11M) | (86.7M) | (137M) |
| EBITDA Margin | -453.2% | -351.8% | -269.8% | -88.1% | -248.1% |
| Operating Income | (446.1M) | (240.24M) | (137.43M) | (105.2M) | (130.77M) |
| Operating Margin | -437.8% | -261.0% | -152.5% | -106.9% | -236.8% |
| Interest Income | 2.73M | 6.78M | 19.01M | 14.5M | 10.44M |
| Interest Expense | 47.31M | 28.91M | 25.33M | 28.11M | 26.18M |
| Other Income / Expenses | (77.18M) | (124.75M) | (138.83M) | (14M) | (33.44M) |
| Income Before Tax | (523.28M) | (364.98M) | (276.26M) | (119.2M) | (164.21M) |
| Pre-Tax Margin | -513.5% | -396.5% | -306.5% | -121.1% | -297.3% |
| Income Tax Expense | 557K | 3.22M | (200K) | (239K) | (138K) |
| Net Income | (523.84M) | (368.2M) | (276.06M) | (118.96M) | (164.08M) |
| Net Margin | -514.0% | -400.0% | -306.3% | -120.9% | -297.1% |
| EPS (Basic) | (42.90) | (29.51) | (21.79) | (8.68) | (9.73) |
| EPS (Diluted) | (42.90) | (29.51) | (21.79) | (8.68) | (9.73) |
| Weighted Avg Shares | 12.22M | 12.48M | 12.67M | 13.71M | 16.87M |
| Weighted Avg Shares (Diluted) | 12.22M | 12.48M | 12.67M | 13.71M | 16.87M |
Nektar Therapeutics
NASDAQ:NKTR
Intrinsic Alpha fair value
Locked
Current Price
$34.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.